Haley Patrick J.

Haley Patrick J., EVP of Commercial at Exelixis, Inc. (EXEL), has demonstrated a consistent pattern of selling company shares over the past several years, as evidenced by SEC Form 4 filings. Out of 25 reported transactions, all were sales, totaling $14,837,827.16 in value. Notably, Haley has not engaged in any purchases of EXEL shares during this period, indicating a clear selling bias. Recent activity includes nine sales between November 2025 and February 2026, with significant transactions such as a $2.82 million sale on February 17, 2026, and a $1.38 million sale on February 15, 2026. Earlier sales include a $1.95 million transaction on February 24, 2025, and multiple sales in November 2025, ranging from $421,100 to $986,990.27. The transactions appear to follow a structured pattern, with sales often occurring around mid-February and mid-November, suggesting potential pre-planned dispositions. Additionally, several filings indicate the use of derivative securities (code "F"), such as options exercises, which are typically part of executive compensation plans. For example, on January 16, 2025, Haley exercised options worth $1.03 million, followed by a sale of shares. This activity aligns with typical executive trading behavior, where options are exercised and shares are sold to realize gains. Haley’s focus on EXEL, the only company involved in these transactions, underscores a concentrated position in the biopharmaceutical firm. The sustained selling trend reflects a consistent reduction in Haley’s equity stake in EXEL over time.